Ken Griffin Cellectar Biosciences, Inc. Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$3.5 - $6.9 $241,465 - $476,031	68,990 New	68,990 $28,000
Q1 2022 May 16, 2022	SELL	$4.6 - $7.8 $757,049 - $1.28 Million	-164,576 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$6.1 - $10.2 $1 Million - $1.68 Million	164,576 New	164,576 $1.09 Million
Q1 2021 May 17, 2021	SELL	$15.2 - $25.0 $519,840 - $855,000	-34,200 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$11.2 - $27.7 $383,040 - $947,340	34,200 New	34,200 $71,000
Q2 2020 Aug 14, 2020	SELL	$10.3 - $17.3 $125,196 - $210,281	-12,155 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$11.0 - $31.7 $133,705 - $385,313	12,155 New	12,155 $15,000
Q2 2019 Aug 14, 2019	SELL	$18.6 - $28.2 $330,336 - $500,832	-17,760 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$15.8 - $28.5 $50,022 - $90,231	3,166 Added 21.69%	17,760 $0
Q4 2018 Feb 14, 2019	BUY	$12.9 - $36.9 $188,262 - $538,518	14,594 New	14,594 $226,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $13M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.